The 9th China Healthcare Investment Conference (CHIC) was held on March 28-29, 2018 in Shanghai. Dr. Zhenkun Ma, Founder and CEO of TenNor Therapeutics, presented TenNor’s recent progress to the conference (please click this link for the presentation: TENNOR 9th CHIC Presentation).

TenNor Therapeutics held its first Clinical Advisory Meeting on TNP-2092 for the treatment of prosthetic joint infections (PJIs) during the American Association of Hip and Knee Surgeons (AAHKS) Meeting in San Francisco on May 5, 2017.

TenNor Therapeutics today announced a $25 million Series B financing led by Northern Light Venture Capital. Joining this round were current investors Frontline BioVentures, WuXi PharmaTech Healthcare Fund I, Oriza Venture Capital and Relativity Healthcare Fund. Proceeds will be used to advance new antibiotics into the late-stage of clinical development.

TenNor’s article “Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections” published recently in the Journal of Medicinal Chemistry has been selected as ACS Editors’ Choice.

TenNor Therapeutics team attended ASM Microbe 2016 Conference held in Boston USA and presented TNP-2092 for Helicobacter pylori infection (HPI) program in public the first time.

TenNor Therapeutics Received Government Grant to Support Development of Dua-Action Molecules for the Treatment of MDR/XDR-TB.

The 10th Chinese H. pylori and Digestive Diseases Forum was held in Beijing on August 21-23, 2015. Established in 2006, the forum has become one of the most important platforms for scientists, gastroenterologists and clinicians in relevant areas to exchange ideas and research results on H. pylori diagnosis and treatment in China. About 800 scientists and clinicians, including 130 nationally and internationally recognized experts in digestive disease area, participated in the meeting. Professor Barry Marshall, Nobel Prize laureate in Physiology or Medicine for his discovery of the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer disease, participated the meeting and give a lecture. Dr. Zhenkun Ma, founder and CEO of TenNor Therapeutics was invited to give a lecture on the development of a new generation of antibiotics for H. pylori eradication.  

Dr. Dennis M. Dixon, Chief, Bacteriology and Mycology Branch, Dr. Lanling Zou, Chief of Translational Sciences and Dr. Ping Chen, Director of China Office, Nation Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH) visited TenNor Therapeutics on May 22, 2015. Dr. Zhenkun Ma, Founder and CEO, provided an update on TenNor’s antibacterial R&D program. Guests from NIH expressed great interests in TenNor’s novel dual-action molecule platform and a series of dual-action compounds in its current development pipeline. Dr. Dennis Dixon and Dr. Lanling Zou presented their work titled Antibacterial Resistance: Needs and Opportunities and Resources for the Microbiology & Infectious Diseases Research Community respectively. The parties agreed to further discuss collaborative opportunities in antibacterial area and reached broad consensus in directions for potential collaboration.